We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > neurofibromatosis

News List

Healx links with CTF to develop neurofibromatosis therapies pharmatimes
April 16, 2020
Cambridge, UK-based Healx has formed a new partnership with US and Europe-based patient group the Children’s Tumor Foundation (CTF) to progress new AI-derived therapies for neurofibromatosis (NF).
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1 worldpharmanews
April 03, 2019
The Association of the British Pharmaceutical Industry has called for a temporary ban on drugs exports in the event of a no-deal Brexit to prevent the NHS being hit by shortages…
AZ and MSD get orphan designation for neurofibromatosis drug pharmatimes
August 06, 2018
The EMA has granted orphan designation to AstraZeneca and MSD's selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).